OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by a combination of arterial and/or venous thrombosis, recurrent fetal loss, often accompanied by a mild-to-moderate thrombocytopenia, and elevated titers of antiphospholipid antibodies (aPL), namely, the lupus anticoagulant (LA) and/or anticardiolipin antibodies (aCL). Antiphospholipid syndrome occurs when r immune system mistakenly attacks some of the normal proteins in blood.
The Euro-Phospholipid Group analyzed the prevalence of the most relevant clinical and immunological features in a cohort of 1000 APS npatients derived from 13 countries. A recent large multicenter study showed that β 2GPI-dependent aPL can be found in almost 10% of ng premenopausal women hospitalized for the first MI.
In antiphospholipid syndrome, body mistakenly produces antibodies against proteins that bind phospholipids, a type of fat present in blood that plays a key role in clotting (coagulation). Antibodies are specialized proteins that normally attack body invaders, such as viruses and bacteria. When antibodies attack phospholipid-binding proteins, blood may clot abnormally.
